BI 51013

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBI 51013

Drug Alias NameAnti-alpha-beta-TCR monoclonal antibody BMA-031Anti-T cell receptor alphabeta monoclonal antibody BMA031BMA 031Monoclonal antibody BMA031Behring Monoclonal Antibody +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionT-cell receptor antagonists

TargetsT-cell receptor

Therapy Area/IndicationsRejection of renal transplantationGraft vs Host Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAventis Behring Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAventis Behring Llc

Active IndicationsN/A

Inactive IndicationsRejection of renal transplantationGraft vs Host Disease

Other Information

ATC CodeN/A